Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3608-3617. doi: 10.1182/bloodadvances.2018023689.

2.

Somatic mutations precede acute myeloid leukemia years before diagnosis.

Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, Roboz GJ, Hassane DC.

Nat Med. 2018 Jul;24(7):1015-1023. doi: 10.1038/s41591-018-0081-z. Epub 2018 Jul 9.

PMID:
29988143
3.

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.

Roboz GJ, Ritchie EK, Dault Y, Lam L, Marshall DC, Cruz NM, Hsu HC, Hassane DC, Christos PJ, Ippoliti C, Scandura JM, Guzman ML.

Haematologica. 2018 Aug;103(8):1308-1316. doi: 10.3324/haematol.2017.183418. Epub 2018 May 3.

4.

Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites.

Poran A, Nötzel C, Aly O, Mencia-Trinchant N, Harris CT, Guzman ML, Hassane DC, Elemento O, Kafsack BFC.

Nature. 2017 Nov 2;551(7678):95-99. doi: 10.1038/nature24280. Epub 2017 Sep 25.

5.

Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.

Cruz NM, Sugita M, Ewing-Crystal N, Lam L, Galetto R, Gouble A, Smith J, Hassane DC, Roboz GJ, Guzman ML.

Leuk Lymphoma. 2018 Apr;59(4):978-982. doi: 10.1080/10428194.2017.1361023. Epub 2017 Aug 10. No abstract available.

6.

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, Hassane DC, Guzman ML.

Leuk Lymphoma. 2018 Apr;59(4):821-828. doi: 10.1080/10428194.2017.1352089. Epub 2017 Jul 18.

7.

Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.

Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A.

Mod Pathol. 2017 Sep;30(9):1213-1222. doi: 10.1038/modpathol.2017.45. Epub 2017 May 26.

8.

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, Ritchie EK, Desai P, Guzman ML, Roboz GJ, Hassane DC.

J Mol Diagn. 2017 Jul;19(4):537-548. doi: 10.1016/j.jmoldx.2017.03.005. Epub 2017 May 16.

9.

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.

Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP.

Cancer. 2017 Jul 15;123(14):2680-2687. doi: 10.1002/cncr.30679. Epub 2017 May 18.

10.

Minimal residual disease in acute myelogenous leukemia.

Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML.

Int J Lab Hematol. 2017 May;39 Suppl 1:53-60. doi: 10.1111/ijlh.12670. Review.

11.

Matrix stiffening promotes a tumor vasculature phenotype.

Bordeleau F, Mason BN, Lollis EM, Mazzola M, Zanotelli MR, Somasegar S, Califano JP, Montague C, LaValley DJ, Huynh J, Mencia-Trinchant N, Negrón Abril YL, Hassane DC, Bonassar LJ, Butcher JT, Weiss RS, Reinhart-King CA.

Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):492-497. doi: 10.1073/pnas.1613855114. Epub 2016 Dec 29.

12.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

13.

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.

Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC.

Mol Cancer Ther. 2014 Aug;13(8):1979-90. doi: 10.1158/1535-7163.MCT-13-0963. Epub 2014 Jun 16.

14.

Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.

Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML.

Exp Hematol. 2013 Sep;41(9):799-807.e4. doi: 10.1016/j.exphem.2013.04.012. Epub 2013 May 6.

15.

Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.

Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H.

Oncogene. 2013 Aug 15;32(33):3809-18. doi: 10.1038/onc.2012.389. Epub 2012 Sep 10.

16.

Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.

Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT.

Cell Stem Cell. 2012 Sep 7;11(3):359-72. doi: 10.1016/j.stem.2012.05.024. Epub 2012 Aug 2.

17.

Acute myelogenous leukemia stem cells: from Bench to Bedside.

Felipe Rico J, Hassane DC, Guzman ML.

Cancer Lett. 2013 Sep 10;338(1):4-9. doi: 10.1016/j.canlet.2012.05.034. Epub 2012 Jun 17. Review.

18.

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.

Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT.

Blood. 2010 Dec 23;116(26):5983-90. doi: 10.1182/blood-2010-04-278044. Epub 2010 Oct 1.

19.

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.

Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT.

Blood. 2008 Jun 15;111(12):5654-62. doi: 10.1182/blood-2007-11-126003. Epub 2008 Feb 27.

20.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT.

Blood. 2007 Dec 15;110(13):4427-35. Epub 2007 Sep 5.

21.

Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells.

Lee RB, Hassane DC, Cottle DL, Pickett CL.

Infect Immun. 2003 Sep;71(9):4883-90.

22.
23.

Cytolethal distending toxin demonstrates genotoxic activity in a yeast model.

Hassane DC, Lee RB, Mendenhall MD, Pickett CL.

Infect Immun. 2001 Sep;69(9):5752-9.

Supplemental Content

Loading ...
Support Center